The interaction of Candida albicans and Helicobacter pylori as a probable impossibility of achieving the goals of eradication therapy: A clinical case

The presented clinical case examines the interaction between two microorganisms, Candida albicans and Helicobacter pylori, and their possible impact on the effectiveness of eradication therapy. Eradication therapy is a set of measures aimed at destroying pathogenic microorganisms in the human body. However, in some cases, achieving complete eradication may be difficult due to interactions with other microorganisms, such as Candida. In the presented clinical case, we are faced with a situation where standard eradication therapy regimens do not allow for complete elimination of H. pylori. The patient has both C. albicans and H. pylori, which can lead to deterioration of the condition and lack of remission of symptoms. In addition, antibiotic resistance may develop. When eradication therapy is prescribed, the patient notes a decrease in clinical symptoms, while a repeat test for H. pylori is positive. After the additional examination (stool for dysbacteriosis with determination of sensitivity to antibacterial drugs, antibodies to parietal cells of the stomach) the therapy was adjusted due to the detection of C. albicans with subsequent control of laboratory parameters to assess the effectiveness of the prescribed therapy. Repeated analysis for H. pylori showed positive dynamics, which indicates the correct choice of patient management tactics. In this regard, it can be concluded that timely diagnosis of candidiasis plays an important role in increasing the effectiveness of treatment and improving the quality of life of a patient with chronic gastritis. This clinical case emphasizes the importance of taking into account the interaction between various microorganisms during eradication therapy. This can help increase its effectiveness and improve the treatment results for patients with infections caused by Helicobacter pylori.

1. Mayev IV, Andreyev DN, Bordin DS, Kucheryavy YuA, Kudryavtseva LV, Vyuchnova YeS et al. Helicobacter pylori Resistance to Clarithromycin in the Russian Federation. Effective Pharmacotherapy. 2020;16(30):16–22. (In Russ.) https://doi.org/10.33978/2307-3586-2020-16-30-16-22.

2. Loranskaya ID, Stepanova EV, Rakitskaya LG, Mammadova LD. Eradication of Helicobacter pylori – ways to achieve effectiveness. RMJ. 2015;(13):748–752. (In Russ.) Available at: https://www.rmj.ru/articles/gastroenterologiya/Eradikaciya_Nelicobacter_pylori__puti_dostigheniya_effektivnosti/.

3. Chen X, Zhou X, Liao B, Zhou Y, Cheng L, Ren B. The cross-kingdom interaction between Helicobacter pylori and Candida albicans. PLoS Pathog. 2021;17(5):e1009515. https://doi.org/10.1371/journal.ppat.1009515.

4. Bačić A, Milivojević V, Petković I, Kekić D, Gajić I, Medić Brkić B et al. In Search for Reasons behind Helicobacter pylori Eradication FailureAssessment of the Antibiotics Resistance Rate and Co-Existence of Helicobacter pylori with Candida Species. J Fungi. 2023;9(3):328. https://doi.org/10.3390/jof9030328.

5. Pereverzev AP, Ostroumova OD. Drug-induced gastrointestinal damage: Part I – types and pathophysiological mechanisms of lesion). Therapy. 2020;(6):171–183. (In Russ.) https://doi.org/10.18565/therapy.2020.6.171-183.

6. Tarhane S. Helicobacter pylori, non- Helicobacter pylori helicobacters and gastrointestinal diseases. Anatolian Curr Med J. 2024;6(6):397–398. https://doi.org/10.38053/acmj.1537177.

7. Romanova MM, Chernov AV, Selyutina MV, Taranina ON. Long-term results of therapy of h. pylori peptic ulcer associated with Helicobacter pylori. Systems Analysis and Management in Biomedical Systems. 2021;20(1):79–85. (In Russ.) https://doi.org/10.36622/VSTU.2021.20.1.011.

8. Sorokin VM, Pisanov RV, Vodop’janov AS, Golubkina EV. New tool for phylogenetic analysis of Helicobacter pylori. World J Adv Res Rev. 2020;6(2):60–67. https://doi.org/10.30574/wjarr.2020.6.2.0128.

9. Golubkina EV, Sorokin VM, Levitan BN, Umerova AR, Kamneva NV. Eradication, Strain Preservation, Strain Change – Outcomes of Helicobacter pylori Therapy. Antibiotiki i Khimioterapiya. 2021;66(3-4):18–26. (In Russ.) https://doi.org/10.37489/0235-2990-2021-66-3-4-18-26.

10. Dekhnich NN, Kozlova MD. Eradication of H. pylori in a patient with giardiasis: a clinical case. Clinical Review for General Practice. 2024;5(6):18–20. (In Russ.) https://doi.org/10.47407/kr2024.5.6.00429.

11. Baryshnikova NV, Zamyatina YuE, Nevskaya YeV. Helicobacter pylori infection and esophageal pathology. University Therapeutic Journal. 2023;5(4):82–93. (In Russ.) https://doi.org/10.56871/UTJ.2023.15.23.007.

12. Bakulina NV, Tikhonov SV, Savilov IV, Zharkov AV, Ponomarenko VA. Dynamics of the prevalence of Helicobacter pylori infection from 2015 to 2023. Herald of North-Western State Medical University named after I.I. Mechnikov. 2023;15(3):41–51. (In Russ.) https://doi.org/10.17816/mechnikov623259.